Literature DB >> 19631349

Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon.

A K Njamnshi1, A C Zoung-Kanyi Bissek, P Ongolo-Zogo, E N Tabah, A Z Lekoubou, F N Yepnjio, J Y Fonsah, C T Kuate, S A Angwafor, F Dema, D M Njamnshi, C Kouanfack, V de P Djientcheu, W F T Muna, G D Kanmogne.   

Abstract

BACKGROUND: The prevalence of HIV-associated neurocognitive disorders (HAND), especially HIV-associated dementia (HAD) is influenced by several risk factors. The prevalence as well as risk factors for HAD are not well known in sub-Saharan Africa (SSA). We have shown that the International HIV Dementia Scale (IHDS) is a useful screening tool for HAND in Yaoundé [Njamnshi AK, Djientcheu VdP, Fonsah JY, Yepnjio FN, Njamnshi DM, Muna WFT. The IHDS is a useful screening tool for HAD/Cognitive Impairment in HIV-infected adults in Yaoundé-Cameroon. Journal of Acquired Immune Deficiency Syndromes 2008;49(4):393-397], but no study in Cameroon has yet investigated the risk factors for HAND or HAD. PATIENTS AND METHODS: A cross-sectional study was conducted in Yaoundé, the capital of Cameroon from September to December 2006. One hundred and eighty-five HIV-positive subjects were included. Diagnosis of HAND was done using the IHDS with a score < or = 10 considered as abnormal. Age, sex, level of education, IV drug use, body mass index (BMI), CDC clinical stage, CD4 counts, hemoglobin levels, administration of highly active antiretroviral therapy (HAART) and type of regimen used, were considered in univariate analysis, with level of significance set at P < or = 0.05. A binary logistic regression was used to determine independent risk factors.
RESULTS: The following factors were independent predictors of HAND: advanced clinical stage (OR=7.43, P=0.001), low CD4 count especially CD4 < or = 200 cells/microL (OR=4.88, P=0.045) and low hemoglobin concentration (OR=1.16, P=0.048).
CONCLUSION: This first study of the risk factors for HAND in Yaoundé-Cameroon shows findings similar to those described in other studies. These results call for rapid action by policy makers to include HAND prevention strategies such as providing early universal access to HAART based on these risk factors, in the management of HIV patients at risk of HAND in resource-limited settings of SSA like ours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631349      PMCID: PMC4906943          DOI: 10.1016/j.jns.2009.06.043

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  30 in total

1.  Second assessment of NeuroAIDS in Africa.

Authors:  Kevin Robertson; Kathy Kopnisky; James Hakim; Concepta Merry; Noeline Nakasujja; Colin Hall; Moussa Traore; Ned Sacktor; David Clifford; Charles Newton; Annelies Van Rie; Penny Holding; Janice Clements; Christine Zink; Jens Mielk; Mina Hosseinipour; Umesh Lalloo; Farida AMod; Christina Marra; Scott Evans; Jeff Liner
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

2.  Measuring handedness with questionnaires.

Authors:  M P Bryden
Journal:  Neuropsychologia       Date:  1977       Impact factor: 3.139

3.  The relationship between age and cognitive function in HIV-infected men.

Authors:  Emily C Kissel; Nicole D Pukay-Martin; Robert A Bornstein
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

4.  Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.

Authors:  Jesús Saavedra-Lozano; José T Ramos; Francisco Sanz; M Luisa Navarro; M I de José; P Martín-Fontelos; María J Mellado; Juan A León Leal; Cecilia Rodriguez; Isabel Luque; Samuel J Madison; David Irlbeck; E Randall Lanier; Octavio Ramilo
Journal:  Pediatr Infect Dis J       Date:  2006-12       Impact factor: 2.129

5.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.

Authors:  L Chang; T Ernst; M Leonido-Yee; M Witt; O Speck; I Walot; E N Miller
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

6.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

7.  Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.

Authors:  E A Childs; R H Lyles; O A Selnes; B Chen; E N Miller; B A Cohen; J T Becker; J Mellors; J C McArthur
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

8.  The International HIV Dementia Scale: a new rapid screening test for HIV dementia.

Authors:  Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

9.  The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaoundé-Cameroon.

Authors:  Alfred K Njamnshi; Vincent de Paul Djientcheu; Julius Y Fonsah; Faustin N Yepnjio; Dora M Njamnshi; Walinjom E Muna
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

10.  Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

Authors:  J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

View more
  28 in total

Review 1.  Paving the path to HIV neurotherapy: Predicting SIV CNS disease.

Authors:  Sarah E Beck; Suzanne E Queen; Kenneth W Witwer; Kelly A Metcalf Pate; Lisa M Mangus; Lucio Gama; Robert J Adams; Janice E Clements; M Christine Zink; Joseph L Mankowski
Journal:  Eur J Pharmacol       Date:  2015-03-24       Impact factor: 4.432

2.  Neurocognitive Impairment Risk Among Individuals With Multiple Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection: Implications for Systematic Linkage to and Retention of Care in Tuberculosis/Human Immunodeficiency Virus Treatment.

Authors:  Andrew Tomita; Suvira Ramlall; Thirusha Naidu; Sbusisiwe Sandra Mthembu; Nesri Padayatchi; Jonathan K Burns
Journal:  J Nerv Ment Dis       Date:  2019-04       Impact factor: 2.254

3.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

4.  Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment.

Authors:  Saurabh Gupta; Jennifer E Iudicello; Chuan Shi; Scott Letendre; Adam Knight; Jianhua Li; Patricia K Riggs; Donald R Franklin; Nichole Duarte; Hua Jin; J Hampton Atkinson; Xin Yu; Zunyou Wu; Igor Grant; Robert K Heaton
Journal:  Drug Alcohol Depend       Date:  2014-01-13       Impact factor: 4.492

Review 5.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

6.  HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia.

Authors:  Adelina Holguin; Mwanza Banda; Elizabeth J Willen; Costantine Malama; Kaseya O Chiyenu; Victor C Mudenda; Charles Wood
Journal:  AIDS Behav       Date:  2011-11

Review 7.  Neurology and the Global HIV Epidemic.

Authors:  Ana-Claire Meyer
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

8.  Up-regulation of the neuronal nicotinic receptor α7 by HIV glycoprotein 120: potential implications for HIV-associated neurocognitive disorder.

Authors:  Leomar Y Ballester; Coral M Capó-Vélez; Wilfredo F García-Beltrán; Félix M Ramos; Edwin Vázquez-Rosa; Raymond Ríos; José R Mercado; Roberto I Meléndez; José A Lasalde-Dominicci
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

9.  HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project.

Authors:  N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi
Journal:  HIV Med       Date:  2014-02-24       Impact factor: 3.180

10.  HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon.

Authors:  Georgette D Kanmogne; Callixte T Kuate; Lucette A Cysique; Julius Y Fonsah; Sabine Eta; Roland Doh; Dora M Njamnshi; Emilienne Nchindap; Donald R Franklin; Ronald J Ellis; John A McCutchan; Fidele Binam; Dora Mbanya; Robert K Heaton; Alfred K Njamnshi
Journal:  BMC Neurol       Date:  2010-07-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.